Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales & Demand Analysis, Number of Procedure Conducted by Biomarker Type & Application The global cancer profiling market will witness a robust CAGR of 11.87%, valued at $9.59 billion in 2021, expected to appreciate and reach $26.31 billion by 2030, confirms Strategic Market Research. Cancer or Tumor profiling is a laboratory test that is conducted to detect gene mutations and the presence of biomarkers and proteins in a tumor tissue sample. Cancer testing at an early stage is very crucial as it detects the presence of cancer before it spreads in the body, thereby making its treatment much easier and more effective. According to IARC (International Agency for cancer research), every 1 out of 5 people develops cancer in due course of their lifetime, whereas 1 out of every 8 men and 1 out of every 11 women across the globe die due to it. In 2019, Cancer was the 2nd major cause of death in the United States. According to CDC (Centers for Disease Control and Prevention), in 2019, approximately 599,601people (2,83,725 females and 315,786 males) died from cancer in the United States. According to GLOBOCAN (Global Cancer Observatory), in the year 2020, there were approximately 19.3 million new cases and 10.3 million deaths due to cancer all across the globe. Breast Cancer in females surpassed lung cancer in 2020, thereby becoming the most common type of diagnosed cancer(11.7%), followed by lung cancer(11.4%), colon cancer (10%), prostate cancer (7.3%), and stomach cancer (5.6%). However, according to ACS journals, Lung cancer remained the major cause of death globally in 2020 (1.8 million deaths or 18%), followed by colon cancer (9.4%), liver cancer (8.3%), stomach cancer (7.7%), and female breast cancer (6.9%). According to ACS Journals, the worldwide cancer burden is estimated to pile up to 28.4 million cases in the year 2040, which is almost close to a 47% rise from 2020. Tumour Mutation Burden is one of the most important characteristics of tumorous tissues that are highly informative for conducting cancer research and testing, thereby influencing the overall market growth worldwide and can be measured by using the NGS (Next Generation Sequencing) technologies. Cancer genomics is the study of tumor genomes using various profiling strategies like DNA methylation and transcriptome that may be collectively defined as omics, facilitating the overall market growth. Single nucleotide variants (SNPs) have the capacity to alter the number of methylation loci, thus resulting in a change of gene expressions, thereby increasing the risk of cancer which in turn is propelling the overall market growth. All the above-mentioned statistics are highly expected to accelerate the growth of the Global cancer profiling market over the forecasted period of 2021-2030. COVID-19 Impact The sudden outbreak of the COVID-19 pandemic had a considerable reverberation on the overall market growth. Cancer testing has largely been put on hold to prioritize the patients' urgent needs in reducing the spread of the Sars-Cov-2 virus. However, according to the American Cancer Society, most healthcare facilities in the United States are on the verge of restarting the process of Cancer Testing after evaluating its various benefits and risks and also ensuring that both the healthcare personnel and the patients are safe from the COVID-19 infection as much as possible. Cancer Profiling Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2020 USD 8.57 Billion The market size value in 2021 USD 9.59 Billion The market size value in 2022 USD 10.73 Billion The market size value in 2023 USD 12.00 Billion The market size value in 2024 USD 13.43 Billion The revenue forecast in 2030 USD 26.31 billion Growth rate CAGR of 11.87 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Based on Technology, Based on Cancer Type, Based on Biomarker Type, Based on Applications, and By region. Based on Technology Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-generation sequencing), Microarrays, In-Situ Hybridization, Others Based on Cancer Type Lung Cancer, Breast Cancer, Colon Cancer, Melanoma Cancer, Prostate Cancer Based on Biomarker Type Protein Biomarkers, Genomic Biomarkers, Others Based on Applications Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Others By Region North America, Europe, Asia-Pacific, and LAMEA Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India, etc. Company Usability Profiles Illumina Inc., NeoGenomics Laboratories Inc., QIAGEN N.V., Genomic Health Inc., Caris Life Sciences, HTG Molecular Diagnostics Inc., Helomics Corporation, Sysmex Corporation, Elevation Oncology, Ribomed Biotechnologies Inc., NanoString Technologies Inc., Guardant Health Inc., Roche Diagnostics, GenScript Biotech Corporation, Tempus Labs, Boreal Genomics Inc, Perthera, Agendia, Omniseq, Histogene X Pricing and purchase options Customized buying options are available to meet your exact research needs. Key Industry Drivers An increase in the number of microbiome effects and the rising prevalence of cancer cases all across the globe are the major factors that are stimulating the overall tumor profiling market growth. According to National Cancer Institute, in 2021, almost 1.9 million people will be diagnosed with cancer in the United States, out of which 2650 men and 281,550 women will be diagnosed with breast cancer. Also, in 2020, the National out-of-pocket costs were maximum for breast cancer (USD3.14 billion), followed by prostate cancer (USD2.26 billion), colon cancer (USD1.46 billion), and lung cancer (USD1.35 billion) hence clearly reflecting the increasing numbers of these type of cancers in the United States. Along with the increasing number of cancer cases across the globe, the rise in usage of various kinds of cancer profiling methods such as comprehensive genomic profiling, comprehensive molecular profiling of lung adenocarcinoma, molecular profiling for precision cancer therapies, molecular profiling of breast cancer, caris tumor profiling, Whole-exome sequencing, Whole genome sequencing, functional profiling cancer, Liquid Biopsy, nanostring immune profiling, Immunohistochemistry, and Biomarker Testing are widely stimulating the overall market growth. Apart from the increasing prevalence of cancer profiling methods, the rise in the number of tests performed by the cancer research centers globally for the detection of sarcoma, melanoma, Fluorescence in situ hybridization, Immuno-oncology, and Non-small cell lung cancer, is fuelling the tumor profiling market growth extensively. Restraints Lack of access to the testing samples, improper conditions of its storage facilities, and rise in usage of immunotherapy are the major factors that are widely restraining the overall market growth. Poor reimbursement scenarios and lack of standard regulations are also obstructing the overall market growth to a great extent. Opportunities The usage of Personalized medicines in oncology has gained immense popularity globally and has become one of the hardcore areas of research in the healthcare industries worldwide. It is expected to change the entire cancer identification, classification, and treatment scenario, thereby yielding substantial future growth in the overall market. Market Analysis Of Different Segments Covered in the Report Based on Technology Immunoassays PCR (Polymerized Chain Reaction) NGS (Next-generation sequencing) Microarrays In-Situ Hybridization Others Based on Cancer Type Lung Cancer Breast Cancer Colon Cancer Melanoma Cancer Prostate Cancer Based on Biomarker Type Protein Biomarkers Genomic Biomarkers Others Based on Applications Research Applications Clinical Applications Screening Diagnostics Prognostics Others Regional Coverage Analysis North America US Mexico Canada Rest of North America Europe Switzerland Russia France Germany U.K Finland Turkey Netherlands Belgium Spain Italy Rest of Europe Asia Pacific China India Indonesia South Korea Thailand Japan Singapore Malaysia Philippines Australia Rest of Asia-Pacific LAMEA Brazil Saudi Arabia Uruguay Argentina Rest of LAMEA Based on Technology, the Immunoassays segment dominated the market in 2020, with a CAGR of 6.89%. The rise in usage of these assays globally to conduct cancer profiling and some of the pivotal suggestions obtained from these assays to decrease the severity of the illnesses and reduce the time duration of hospital stays are widely facilitating the growth of this segment. Based on Cancer Type, the ‘Breast Cancer segment dominated the market significantly in 2020. According to WHO, breast cancer recorded the highest number of cases in 2020, with 2.26 million cases worldwide. Based on Biomarker Type, the the‘GenomicBiomarkers’ dominated the market with a CAGR of 6.713% over the forecasted period of 2020-2028. The continuous rise in the usage of these biomarkers globally in cancer diagnosis and cancer prognosis has resulted in comprehensive genomic profiling, which in turn is driving the growth of this segment. Based on Applications, the ‘Research Applications’ accounted for the largest market share with a CAGR of 7.93%. The rise in funding for the development of cancer research and testing centers all across the globe, an increase in usage of personalized medicine, and a sheer focus on the discovery of biomarkers for drug development are widely propelling the growth of this segment. Based on Regions, North America dominated the market in 2020, with the largest market share of 48.08% of all cancer diagnoses performed across the globe with a steady CAGR. Huge funding available for conducting R&D projects on Cancer/Tumor Profiling and the continuous growth of advanced cancer screening technologies is fuelling the market growth in this region. However, the APAC region exhibited the highest growth rate with a CAGR of 7.23% over the forecasted period of 2020-2028. Cancer Profiling Market Competitive Landscape Analysis Competitive Landscape Analysis is widely used for adequate identification of competitors that exist in the market across the globe. The comparison is solely performed based on the expenditure in the R&D company overview and financials, global presence, overall revenue generated, market capability, market initiatives, production capacity, production sites, its different facilities, organization flaws, strengths, etc. Illumina Inc. NeoGenomics Laboratories Inc. QIAGEN N.V. Genomic Health Inc. Caris Life Sciences HTG Molecular Diagnostics Inc. Helomics Corporation Sysmex Corporation Elevation Oncology Ribomed Biotechnologies Inc. NanoString Technologies Inc. Guardant Health Inc. Roche Diagnostics GenScript Biotech Corporation Tempus Labs Boreal Genomics Inc Perthera Agendia Omniseq Histogene X Recent Developments On August 2021, Illumina acquired GRAIL for accelerating patient access to life-saving early tests of multiple types of cancers. GRAIL’s Galleri Blood Test has the capacity to detect almost 50 different types of cancers before they are symptomatic. The acquisition of Illumina over GRAIL will highly accelerate the adoption rate of these life-saving tests all across the globe. On March 2021, Elevation Oncology and NeoGenomics jointly announced a collaboration to expand the genomic testing of NRG1 Fusions across solid tumors to support the Phase two CRESTONE study. On May 2019, Caris Life Sciences received FDA approval in granting the Breakthrough Device Designation for the MI transcriptome Companion diagnostic test. It accurately detects gene fusions in solid tumors. The Key Devices that the Leading Organizations Develop Product Name Function Company AmpliSeq for Illumina BRCA Panel A target resequencing assay that is used for research on germile and somatic variants across BRCA 1 and BRCA 2 genes, which are also called tumor suppressor genes, reduces the risk of developing ovarian and breast cancers. Illumina Inc ChemoFx Identification of treatments for Epithelial Ovarian cancer Genomic Health Inc. GeoMx CTA (Cancer Transcriptome Atlas) Comprehensive profiling of tumor microenvironment tumor biology and the immune response NanoString Technologies Inc Frequently Asked Question About This Report Which is the most dominant region of the market? North America is the most dominant region for the market with the largest market share of 48.08% of all cancer diagnoses performed across the globe throughout the forecasted period of 2020-2028. Who are the pivotal industry players of the market? The most vital industry players of the market are Illumina Inc, NeoGenomics Laboratories Inc, QIAGEN N.V., Genomic Health Inc, Caris Life Sciences, HTG Molecular Diagnostics Inc, Helomics Corporation, Sysmex Corporation, Ribomed Biotechnologies Inc, NanoString Technologies Inc, Guardant Health Inc, Roche Diagnostics, GenScript Biotech Corporation, Tempus Labs, Boreal Genomics Inc, Perthera, Agendia, Omniseq, and Histogene X. Which is the leading technology segment of the market? The leading technological segment of the market is the ‘‘Immunoassays’ segment with an overall CAGR of 6.89%. What are the current trends and advancements in the market? The current trends and advancements in the market are, increasing in implementations of OMICs (proteomics, genomics,epigenetics, and metabolomics,) to develop personalized medicines for cancer management and the rising prevalence of several methods of cancer tests across the globe. How big is the Cancer Tumor Profiling market? The global Cancer Tumor Profiling market size was $ 9.59 Bn in 2021 and is predicted to reach $ 26.31 Bn by 2030, with a CAGR of 5.37%. What is the Cancer Tumor Profiling market growth? The global Cancer Tumor Profiling market is expected to grow at a compound annual growth rate (CAGR) of 5.37% from 2021 to 2030 to reach USD 26.31 Billion by 2030. Sources https://www.iarc.who.int/wp-content/uploads/2020/12/pr292_E.pdf https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21660 https://seer.cancer.gov/statfacts/html/common.html 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Market 4.2.1 Global Cancer/Tumor Profiling Market, 2020 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021 - 2030 (USD Million) 4.4 By Technology Business Analysis 4.4.1 Market, By Technology, 2021 - 2030 (USD Million) 4.5 By Cancer Type Business Analysis 4.5.1 Market, By Cancer Type, 2021 - 2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Market, By Application, 2021 - 2030 (USD Million) 4.6 Biomarker Type Business Analysis 4.6.1 Market, By Biomarker Type, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Technology Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Immunoassays 7.3.1. Immunoassays market, 2021 - 2030 (USD Million) 7.4. PCR (Polymerized Chain Reaction) 7.4.1. PCR (Polymerized Chain Reaction) market, 2021 - 2030 (USD Million) 7.5. NGS (Next-generation sequencing) 7.5.1. NGS (Next-generation sequencing) market, 2021 - 2030 (USD Million) 7.6. Microarrays 7.6.1. Microarrays market, 2021 - 2030 (USD Million) 7.7. In-Situ Hybridization 7.7.1. NGS In-Situ Hybridization market, 2021 - 2030 (USD Million) 7.8. Others 7.8.1. Others market, 2021 - 2030 (USD Million) 8. Global Market: By Cancer Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Lung Cancer 8.3.1. Lung Cancer market, 2021 - 2030 (USD Million) 8.4. Breast Cancer 8.4.1. Breast Cancer market, 2021 - 2030 (USD Million) 8.5. Colon Cancer 8.5.1. Colon Cancer market, 2021 - 2030 (USD Million) 8.6. Melanoma Cancer 8.6.1. Melanoma Cancer market, 2021 - 2030 (USD Million) 8.7. Prostate Cancer 8.7.1. Prostate Cancer market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Research Applications 9.3.1. Research Applications market, 2021 - 2030 (USD Million) 9.4. Clinical Applications 9.4.1. Clinical Applications market, 2021 - 2030 (USD Million) 9.5 Screening 9.5.1 Screening market, 2021 - 2030 (USD Million) 9.6. Diagnostics 9.6.1. Diagnostics market, 2021 - 2030 (USD Million) 9.7. Prognostics 9.7.1. Prognostics market, 2021 - 2030 (USD Million) 9.8. Others 9.8.1. Others market, 2021 - 2030 (USD Million) 10. Global Market: By Biomarker Type Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Protein Biomarkers 10.3.1. Protein Biomarkers market, 2021 - 2030 (USD Million) 10.4. Genomic Biomarkers 10.4.1. Genomic Biomarkers market, 2021 - 2030 (USD Million) 10.5 Others 10.5.1 Others market, 2021 - 2030 (USD Million) 11. Global Market: Regional Outlook 11.1 North America 11.1.1. North America market, By Technology, 2021 - 2030 (USD Million) 11.1.2. North America market, By Cancer Type, 2021 - 2030 (USD Million) 11.1.3. North America market, by Application, 2021 - 2030 (USD Million) 11.1.4. North America market, By Biomarker Type, 2021 - 2030 (USD Million) 11.1.5. North America market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, By Technology, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, By Cancer Type, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by Application, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, By Technology, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, By Cancer Type, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by Application, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, By Technology, 2021 - 2030 (USD Million) 11.2.1. Europe market, by By Biomarker Type, 2021 - 2030 (USD Million) 11.2.2. Europe market, By Cancer Type, 2021 - 2030 (USD Million) 11.2.3. Europe market, by Application, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, By Technology, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, By Cancer Type, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by Application, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, By Technology, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, By Cancer Type, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by Application, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, By Technology, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, By Cancer Type, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by Application, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, By Technology, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, By Cancer Type, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by Application, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, By Technology, 2021 - 2030 (USD Million) 11.3.1. Asia Pacific market, By Biomarker Type, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by Application, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, By Technology, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by Application, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, By Technology, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by Application, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, By Technology, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by Application, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, By Technology, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by Application, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, By Technology, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, By Cancer Type, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by Application, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, By Technology, 2021 - 2030 (USD Million) 11.4.2. Latin America market, By Cancer Type, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by Application, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, By Technology, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, By Cancer Type, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by Application, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, By Technology, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, By Cancer Type, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by Application, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America market, By Technology, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, By Cancer Type, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by Application, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, By Technology, 2021 - 2030 (USD Million) 11.5.2. MEA market, By Cancer Type, 2021 - 2030 (USD Million) 11.5.3. MEA market, by Application, 2021 - 2030 (USD Million) 11.5.4. MEA market, By Biomarker Type, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 Illumina Inc. 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Product Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Neo Genomics Laboratories Inc. 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Product Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. QIAGEN N.V. 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Product Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Genomic Health Inc. 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Product Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. Caris Life Sciences 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Product Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. HTG Molecular Diagnostics Inc. 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Product Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. Helomics Corporation 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Product Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. Sysmex Corporation. 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Product Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. Elevation Oncology. 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 12.10. Ribomed Biotechnologies Inc. 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Product Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. NanoString Technologies Inc. 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Product Portfolio Analysis 12.11.4. Business Strategy & Recent Development 12.12. Guardant Health Inc. 12.12.1. Company overview 12.12.2. Financial performance 12.12.3. Product Portfolio Analysis 12.12.4. Business Strategy & Recent Development 12.13. Roche Diagnostics 12.13.1. Company overview 12.13.2. Financial performance 12.13.3. Product Portfolio Analysis 12.13.4. Business Strategy & Recent Development 12.14. GenScript Biotech Corporation. 12.14.1. Company overview 12.14.2. Financial performance 12.14.3. Product Portfolio Analysis 12.14.4. Business Strategy & Recent Development 12.15. Tempus Labs. 12.15.1. Company overview 12.15.2. Financial performance 12.15.3. Product Portfolio Analysis 12.15.4. Business Strategy & Recent Development 12.16. Boreal Genomics Inc. 12.16.1. Company overview 12.16.2. Financial performance 12.16.3. Product Portfolio Analysis 12.16.4. Business Strategy & Recent Development 12.17. Perthera. 12.17.1. Company overview 12.17.2. Financial performance 12.17.3. Product Portfolio Analysis 12.17.4. Business Strategy & Recent Development 12.18. Agendia. 12.18.1. Company overview 12.18.2. Financial performance 12.18.3. Product Portfolio Analysis 12.18.4. Business Strategy & Recent Development 12.19. Omniseq. 12.19.1. Company overview 12.19.2. Financial performance 12.19.3. Product Portfolio Analysis 12.19.4. Business Strategy & Recent Development 12.20. Histogene X. 12.20.1. Company overview 12.20.2. Financial performance 12.20.3. Product Portfolio Analysis 12.20.4. Business Strategy & Recent Development List of Tables (77 Tables) TABLE 1. MARKET, By Technology, 2021-2030 (USD Million) TABLE 2. MARKET FOR Immunoassays, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR PCR (Polymerized Chain Reaction), BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR NGS (Next-generation sequencing), BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Microarrays, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR In-Situ Hybridization, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, By Cancer Type, 2021-2030 (USD Million) TABLE 9. MARKET FOR Lung Cancer, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Breast Cancer, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Colon Cancer, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Melanoma Cancer, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Prostate Cancer, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 15. MARKET FOR Research Applications, BY REGION, 2021-2030 (USD Million) TABLE 16. MARKET FOR Clinical Applications, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Screening, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Diagnostics, BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET FOR Prognostics, BY REGION, 2021-2030 (USD Million) TABLE 20. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA MARKET, By Technology, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA MARKET, By Cancer Type, 2021-2030 (USD Million) TABLE 25. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 26. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 27. EUROPE MARKET, By Technology, 2021-2030 (USD Million) TABLE 28. EUROPE MARKET, By Cancer Type, 2021-2030 (USD Million) TABLE 29. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 31. ASIA-PACIFIC MARKET, By Technology, 2021-2030 (USD Million) TABLE 32. ASIA-PACIFIC MARKET, By Cancer Type, 2021-2030 (USD Million) TABLE 33. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 34. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 35. LAMEA MARKET, By Technology, 2021-2030 (USD Million) TABLE 36. LAMEA MARKET, By Cancer Type, 2021-2030 (USD Million) TABLE 37. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 38. Illumina Inc. : COMPANY SNAPSHOT TABLE 39. Illumina Inc. : OPERATING SEGMENTS TABLE 40. NeoGenomics Laboratories Inc. : COMPANY SNAPSHOT TABLE 41. NeoGenomics Laboratories Inc. : OPERATING SEGMENTS TABLE 42. QIAGEN N.V. : COMPANY SNAPSHOT TABLE 43. QIAGEN N.V. : OPERATING SEGMENTS TABLE 44. Genomic Health Inc.: COMPANY SNAPSHOT TABLE 45. Genomic Health Inc.: OPERATING SEGMENTS TABLE 46. Caris Life Sciences: COMPANY SNAPSHOT TABLE 47. Caris Life Sciences: OPERATING SEGMENTS TABLE 48. HTG Molecular Diagnostics Inc.: COMPANY SNAPSHOT TABLE 49. HTG Molecular Diagnostics Inc.: OPERATING SEGMENTS TABLE 50. Helomics Corporation: COMPANY SNAPSHOT TABLE 51. Helomics Corporation: OPERATING SEGMENTS TABLE 52. Sysmex Corporation: COMPANY SNAPSHOT TABLE 53. Sysmex Corporation: OPERATING SEGMENTS TABLE 54. Elevation Oncology: COMPANY SNAPSHOT TABLE 55. Elevation Oncology: OPERATING SEGMENTS TABLE 56. Ribomed Biotechnologies Inc.: COMPANY SNAPSHOT TABLE 57. Ribomed Biotechnologies Inc.: OPERATING SEGMENTS TABLE 58. NanoString Technologies Inc.: COMPANY SNAPSHOT TABLE 59. NanoString Technologies Inc.: OPERATING SEGMENTS TABLE 60. Guardant Health Inc.: COMPANY SNAPSHOT TABLE 61. Guardant Health Inc.: OPERATING SEGMENTS TABLE 62. Roche Diagnostics: COMPANY SNAPSHOT TABLE 63. Roche Diagnostics: OPERATING SEGMENTS TABLE 64. GenScript Biotech Corporation: COMPANY SNAPSHOT TABLE 65. GenScript Biotech Corporation: OPERATING SEGMENTS TABLE 66. Tempus Labs: COMPANY SNAPSHOT TABLE 67. Tempus Labs: OPERATING SEGMENTS TABLE 68. Boreal Genomics Inc: COMPANY SNAPSHOT TABLE 69. Boreal Genomics Inc: OPERATING SEGMENTS TABLE 70. Perthera : COMPANY SNAPSHOT TABLE 71. Perthera: OPERATING SEGMENTS TABLE 72. Agendia: COMPANY SNAPSHOT TABLE 73. Agendia: OPERATING SEGMENTS TABLE 74. Omniseq: COMPANY SNAPSHOT TABLE 75. Omniseq: OPERATING SEGMENTS TABLE 76. Histogene X: COMPANY SNAPSHOT TABLE 77. Histogene X: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 20 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Cancer/Tumor Profiling, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Cancer/Tumor Profiling, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Cancer Type, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Technology, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Biomarker Type, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Immunoassays to Witness Higher CAGR in Market for Technology Segment during Forecast Period. Figure 17 Breast Cancer to Witness Higher CAGR in Market for Cancer Type Segment during Forecast Period. Figure 18 Genomic Biomarkers to Witness Higher CAGR in Market for Biomarker Type Segment during Forecast Period. Figure 19 Research Applications to Witness Higher CAGR in Market for Applications Segment during Forecast Period. Figure 20 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 21 Market: Drivers, Restraints, Opportunities, and Challenges Figure 22 North America: Market Snapshot Figure 23 Asia Pacific: Market Snapshot Figure 24 Vendor Dive: Evaluation Overview